About Rznomics
Rznomics is a publicly listed company based in Yongin (South Korea) founded in 2017 by Seong-Wook Lee. It operates as a developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology. Rznomics has raised $39.8 million across 2 funding rounds from investors including SBI Mutual Fund, SBI Investment Korea and Korea Development Bank Europe. Its chief executive is Seong-Wook Lee. Its website rznomics.com draws about 23 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Rgenomics Co., Ltd. Its competitors include Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Revolution Medicines and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Rznomics was founded in 2017 as a biotechnology firm specializing in RNA platform technology for drug development. Gene therapy products are created to address cancers, degenerative conditions, hereditary liver diseases, and related disorders. Operations focus on innovative treatments, with lead candidates including RZ001 for cancer, RZ002, and RZ003 targeted at Alzheimers disease. The company operates within the pharmaceutical sector, emphasizing RNA-based solutions for unmet medical needs.
- Headquarters Yongin, South Korea
- Founders Seong-Wook Lee
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website rznomics.com
- Social LinkedIn
- Legal Name Rznomics Inc.
- Annual Revenue$5.48 M (USD)0as on Dec 31, 2025
- Net Profit-$71.84 M (USD)-450.72as on Dec 31, 2025
- EBITDA-$9.41 M (USD)-15.45as on Dec 31, 2025
- Total Equity Funding$39.8M (USD)
in 2 rounds
- Latest Funding Round$29.76M (USD), Series C
Jun 2022
- InvestorsSBI Mutual Fund
& 10 more
Funding Insights of Rznomics
Rznomics has successfully raised a total of $39.8M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $29.76 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $39.8M
- Total Rounds 2
- Last Round Series C — $29.76M
- First Round $10.04M
(Sep 2019)
- Investors Count 11
All 2 funding rounds of Rznomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $29.76M | Series C | – | – | |
| Sep 2019 | $10.04M | Series A | – | SBI Investment Korea, Korea Development Bank Europe | – |
11 investors in total: 11 institutional.
Investors in Rznomics
Rznomics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include SBI Mutual Fund, SBI Investment Korea and Korea Development Bank Europe.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment services are offered by AON Investment in Seoul. | – | aoninvest.co.kr | Seoul, South Korea | |
PE firm investing in South Korea and the US | – | partnersi.co.kr | Seoul, South Korea | |
- | – | ibkcapital.co.kr | - | |
Sector-agnostic VC firm investing in geographies such as South Korea | 1986 | sbik.co.kr | Seoul, South Korea | |
Provider of a venture capital firm for various sectors | – | shinhanvc.com | Seoul, South Korea | |
- | – | lski.co.kr | - | |
Investment services are provided focusing on mezzanine and value creation. | 2014 | synergyib.co.kr | Seoul, South Korea | |
Operates as a commercial bank providing deposits, loans, and payment services to customers. | 1989 | kdbbank.eu | Budapest, Hungary | |
Provides mutual funds management and financial advisory services. | 1987 | sbimf.com | Mumbai, India | |
Investment management services are provided by QUAD Investment Management. | – | quadim.com | Seoul, Korea |
Investor details for Rznomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rznomics
1 people are tracked at Rznomics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Seong-Wook Lee | Founder & CEO | Leadership |
Complete people profiles for Rznomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Rznomics
Rznomics is a publicly listed company on the KRX with ticker symbol 476830 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Dec 2025
- Listed onKRX: 476830
- Listed entityRznomics Inc.
- Exchange sectorHealth technology
- ISINKR7476830005
- Share price22,200.00 KRW (-1.11% on the day) · 2026-10-14
- Market capitalisation629,844,519,806.00 KRW
- EPS (diluted, trailing year)-996.15 KRW
- Volume (last session)308,407
Financials of Rznomics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 7.92B KRW | -103.81B KRW | -13.60B KRW |
| 2024 | – | -18.85B KRW | -11.78B KRW |
| 2023 | 143.6M KRW | -13.60B KRW | -14.57B KRW |
| 2022 | – | -31.53B KRW | -18.49B KRW |
Detailed financial statements for Rznomics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Rznomics
4 dated milestones of Rznomics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Rznomics is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series C, of $29.8M.
- IPO Lists on the stock exchange (IPO).
Competitors of Rznomics
Rznomics has 9 listed competitors in our database, 9 of them funded. They include Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Revolution Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Rznomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rznomics
The website of Rznomics (rznomics.com) receives about 22.7K visits a month.
- Monthly visits22.7K
▲ 12.9% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Rznomics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rznomics
Complete news archive for Rznomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rznomics
Rznomics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Rznomics is headquartered in Yongin, South Korea. It is registered at Yongin, Gyeonggi, South Korea.
Seong-Wook Lee is the current CEO of Rznomics. They have also founded this company.
Rznomics is a funded company, having raised a total of $39.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10.04M, raised on Sep 2019.
Annual revenue of Rznomics is $5.48M as on Dec 31, 2025.
Rznomics was founded in 2017 as a biotechnology firm specializing in RNA platform technology for drug development. Gene therapy products are created to address cancers, degenerative conditions, hereditary liver diseases, and related disorders. Operations focus on innovative treatments, with lead candidates including RZ001 for cancer, RZ002, and RZ003 targeted at Alzheimers disease. The company operates within the pharmaceutical sector, emphasizing RNA-based solutions for unmet medical needs.
Rznomics's top competitors include Moderna, Jazz Pharmaceuticals and Spark Therapeutics.
Yes, Rznomics is publicly traded on KRX under the ticker symbol 476830.
Rznomics has 11 investors. Key investors include SBI Mutual Fund, SBI Investment Korea, Korea Development Bank Europe, AON Investment, and Partners Investment.
Rznomics operates through Rgenomics Co., Ltd..